Format

Send to

Choose Destination
Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7.

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.

Author information

1
Department of Neurology, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Shenyang, Liaoning 110004, China. Electronic address: zjli@cmu.edu.cn.
2
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Shenyang, Liaoning 110004, China.
3
Immune Therapeutics, Inc., 37 North Orange Ave., Suite 607, Orlando, FL 32801, USA. Electronic address: Noreen.Griffin@immunetherapeutics.com.
4
Department of Neurology, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Shenyang, Liaoning 110004, China. Electronic address: juanfeng@cmu.edu.cn.
5
Department of Immunology, School of Basic Medical Science, China Medical University, No. 77, Puhe Road, Shenyang, Liaoning 110122, China. Electronic address: fpshan@cmu.edu.cn.

Abstract

Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases. In this article, we review the pharmacological functions and mechanisms of LDN as well as its clinical therapeutic potential as revealed by our team and other researchers.

KEYWORDS:

Cancer; Crohn's disease; Immune; Inflammation; Low dose naltrexone; Multiple sclerosis

PMID:
29885638
DOI:
10.1016/j.intimp.2018.05.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center